When a person with Parkinson's or a relative wants to find out about a possible disease, accompanying symptoms play a crucial role. These can affect different parts of the body, including skin, skeleton, sensory organs and psyche. The severity and occurrence of these symptoms vary from person to person, and it is important to note that some symptoms may have other causes.
However, the perspectives changed fundamentally with the introduction of Produodopa®, a subcutaneous infusion solution. Continuous infusion over 24 hours using a portable pump ensures more constant effective levels. The crucial advantage for all of us is that no surgery is required to insert the subcutaneous cannula. This less invasive treatment option is a huge relief for all of us.
The increased risk of melanoma in Parkinson's patients has been documented in numerous scientific studies. A first comprehensive meta-analysis was published by Liu and colleagues in the journal Neurology in 2011 and found that people with Parkinson's had more than double the risk of being diagnosed with melanoma. An important study on this topic was also published in 2010 by John Bertoni and colleagues in the Archives of Neurology (later renamed JAMA Neurology). The Bertoni study used data from the North American Parkinson's and Melanoma Survey Group and found that the incidence of malignant melanoma was 2,24 times higher in the Parkinson's cohort compared to the general population.